U.S. License Holder:
Boehringer Ingelheim Pharmaceuticals Inc.
Date of License:
September-01-2022
Last Update:
Sep-30-2024
FDA-Approved Indications
SPEVIGO (spesolimab-sbzo) is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.